drugset / Trial / NCT02417935

A Study of Duloxetine (LY248686) in Participants With Diabetic Peripheral Neuropathic Pain (DPNP)

NCT02417935

Phase 4 Completed 304 enrolled Eli Lilly and Company Shionogi · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The main purpose of this study is to evaluate the effectiveness and safety of the study drug known as duloxetine in participants with diabetic peripheral neuropathic pain.

Timeline

Start
2015-04
Primary completion
2017-05-13
Completion
2017-05-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Duloxetine Small molecule 40 mg Oral
Subject Duloxetine Small molecule 60 mg Oral
Comparator Pregabalin Small molecule 300 mg Oral
Comparator Pregabalin Small molecule 600 mg Oral